Roche has received FDA approval for subcutaneous injectable versions of two of its biologic drugs, Tecentriq Hybreza for cancer and Ocrevus Zunovo for multiple sclerosis. The subcutaneous injections significantly reduce dosing time, with Tecentriq Hybreza requiring a seven-minute injection every three weeks compared to a 30-60 minute IV infusion. The FDA approval was based on studies showing the injectable versions were comparable to the infused drugs in terms of efficacy and safety. The subcutaneous versions offer patients more flexibility and convenience in treatment administration. These drugs will help Roche compete against other MS medicines on the market.
Source link
Roche Welcomes FDA Approvals for Injectable Versions of MS and Cancer Drugs
